Specific risk scores for specific purposes: Use CHA2DS 2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation

Thrombosis Research

Volumn 134, Issue 2, 2014, Pages 217-218

  Dzeshka, Mikhail S ^a,b   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b GRODNO STATE MEDICAL UNIVERSITY   (Belarus)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG USE; EDITORIAL; HAS BLED SCORE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MASS SCREENING; PRACTICE GUIDELINE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYSTEMATIC REVIEW (TOPIC); THROMBOEMBOLISM; VASCULAR DISEASE; ATRIAL FIBRILLATION; COMPLICATION; HEMORRHAGE; STROKE;

ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; RISK ASSESSMENT; STROKE;

EID: 84905107904     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.06.003     Document Type: Editorial

References (19)

1. N. Lowres, L. Neubeck, J. Redfern, and S.B. Freedman Screening to identify unknown atrial fibrillation. A systematic review Thromb Haemost 110 2 2013 213 222
2. N. Lowres, L. Neubeck, G. Salkeld, I. Krass, A.J. McLachlan, and J. Redfern et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study Thromb Haemost 111 6 2014 1167 1176
3. M. Grond, M. Jauss, G. Hamann, E. Stark, R. Veltkamp, and D. Nabavi et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study Stroke 44 12 2013 3357 3364
4. R. De Caterina, S. Husted, L. Wallentin, F. Andreotti, H. Arnesen, and F. Bachmannet et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease Thromb Haemost 110 6 2013 1087 1107
5. P. Gallego, V. Roldan, F. Marín, M. Romera, M. Valdés, and V. Vicente et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb Haemost 110 6 2013 1189 1198
6. G.Y. Lip Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 34 14 2013 1041 1049
7. N.S. Roskell, M. Samuel, H. Noack, and B.U. Monz Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies Europace 15 6 2013 787 797
8. L. Friberg, M. Rosenqvist, and G. Lip Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish Atrial Fibrillation Cohort Study Circulation 125 2012 2298 2307
9. 2 experience Thromb Res 134 2014 495 502 [in this issue]
10. M. Marcucci, G.Y. Lip, R. Nieuwlaat, R. Pisters, H.J. Crijns, and A. Iorio Stroke and bleeding risk co-distribution in real-word patients with atrial fibrillation: the Euro Heart Survey Am J Med 2014 10.1016/j.amjmed.2014.05.003 [Epub ahead of print]
11. S. Apostolakis, D.A. Lane, H. Buller, and G.Y. Lip Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial Thromb Haemost 110 5 2013 1074 1079
12. 2-VASc scores in anticoagulated patients with atrial fibrillation J Am Coll Cardiol 62 23 2013 2199 2204
13. G.Y. Lip, D.A. Lane, H. Buller, and S. Apostolakis Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: The AMADEUS Study Chest 144 6 2013 1839 1847
14. A. Banerjee, L. Fauchier, A. Bernard-Brunet, N. Clementy, and G.Y. Lip Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project Thromb Haemost 111 3 2014 549 556
15. V. Roldán, F. Marín, H. Fernández, S. Manzano-Fernandez, P. Gallego, and M. Valdés et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy Chest 143 1 2013 179 184
16. S. Apostolakis, D.A. Lane, Y. Guo, H. Buller, and G.Y. Lip Performance of the Hemorr(2)hages, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: The AMADEUS (evaluating the use of sr34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) Study J Am Coll Cardiol 60 2012 861 867
17. G.Y. Lip, A. Banerjee, I. Lagrenade, D.A. Lane, S. Taillandier, and L. Fauchier Assessing the risk of bleeding in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project Circ Arrhythm Electrophysiol 5 5 2012 941 948
18. H. Omran, R. Bauersachs, S. Rubenacker, F. Goss, and C. Hammerstingl The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the National Multicentre BNK Online Bridging Registry (BORDER) Thromb Haemost 108 2012 65 73
19. G.Y. Lip, H.J. Lin, H.C. Hsu, T.C. Su, M.F. Chen, and Y.T. Lee et al. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study Int J Cardiol 168 3 2013 1832 1836